HilleVax (NASDAQ:HLVX) Trading Up 24.8%

HilleVax, Inc. (NASDAQ:HLVXGet Rating)’s stock price was up 24.8% during mid-day trading on Wednesday . The stock traded as high as $17.32 and last traded at $17.05. Approximately 12,841 shares changed hands during trading, a decline of 53% from the average daily volume of 27,537 shares. The stock had previously closed at $13.66.

Wall Street Analyst Weigh In

Several research analysts have issued reports on HLVX shares. JPMorgan Chase & Co. started coverage on HilleVax in a report on Tuesday, May 24th. They set an “overweight” rating and a $24.00 price objective on the stock. Guggenheim assumed coverage on shares of HilleVax in a research report on Tuesday, May 24th. They set a “buy” rating and a $40.00 target price for the company. Stifel Nicolaus assumed coverage on shares of HilleVax in a research report on Tuesday, May 24th. They set a “buy” rating and a $34.00 target price for the company. Finally, SVB Leerink assumed coverage on shares of HilleVax in a research report on Tuesday, May 24th. They set an “outperform” rating and a $30.00 target price for the company.

HilleVax Price Performance

The company has a current ratio of 25.54, a quick ratio of 25.54 and a debt-to-equity ratio of 0.02. The company’s 50-day simple moving average is $12.80.

HilleVax (NASDAQ:HLVXGet Rating) last released its quarterly earnings data on Wednesday, June 8th. The company reported ($10.06) EPS for the quarter, missing analysts’ consensus estimates of ($3.68) by ($6.38). On average, research analysts expect that HilleVax, Inc. will post -8.23 earnings per share for the current year.

Institutional Trading of HilleVax

A number of large investors have recently made changes to their positions in HLVX. Frazier Life Sciences Management L.P. bought a new stake in shares of HilleVax in the 2nd quarter valued at $101,493,000. Deerfield Management Company L.P. Series C bought a new position in HilleVax during the 2nd quarter worth about $28,614,000. Price T Rowe Associates Inc. MD bought a new position in HilleVax during the 2nd quarter worth about $12,037,000. Franklin Resources Inc. bought a new position in HilleVax during the 2nd quarter worth about $7,351,000. Finally, State Street Corp bought a new position in HilleVax during the 2nd quarter worth about $1,794,000.

HilleVax Company Profile

(Get Rating)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Featured Stories

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.